Wide Ranks

ENTA

Enanta Pharmaceuticals, Inc.

8.83

Top Statistics
Market Cap 187 M Forward PE -1.50 Revenue Growth -4.90 %
Current Ratio 4.92 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -160.27 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.55 Enterprise / Revenue 2.60 Price To Sales Trailing12 Months 2.60
Profitability
Profit Margins -160.27 % Operating Margins -134.58 %
Balance Sheet
Total Cash 230 M Total Cash Per Share 10.86 Total Debt 226 M
Total Debt To Equity 151.88 Current Ratio 4.92 Book Value Per Share 7.03
All Measures
Short Ratio 2091.00 % Message Board Id finmb_345286 Fax 617 607 0530
Shares Short Prior Month 2 M Return On Equity -0.5964 City Watertown
Uuid 0716474a-69e6-3365-b278-ac9fe128aaa5 Previous Close 8.56 First Trade Date Epoch Utc 1 B
Book Value 7.03 Beta 0.5680 Total Debt 226 M
Volume 233424 Price To Book 1.26 Fifty Two Week Low 8.00
Total Cash Per Share 10.86 Total Revenue 71 M Shares Short Previous Month Date 1 B
Target Median Price 17.00 Audit Risk 3 Max Age 86400
Recommendation Mean 2.38 Sand P52 Week Change 0.3133 Operating Margins -134.58 %
Target Mean Price 18.12 Net Income To Common -115329000 Short Percent Of Float 0.1726
Implied Shares Outstanding 21 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 284160 Average Volume10days 284160 Total Cash 230 M
Next Fiscal Year End 1 B Revenue Per Share 3.41 Held Percent Insiders 0.0609
Ebitda Margins -167.23 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 8.56
Target Low Price 9.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 10.92
Open 8.51 Free Cashflow -63273624 State MA
Dividend Yield 0.00 % Return On Assets -0.1718 Time Zone Short Name EST
Board Risk 4 Trailing Eps -5.48 Day Low 8.49
Address1 500 Arsenal Street Shares Outstanding 21 M Compensation Risk 7
Price Hint 2 Target High Price 30.00 Website https://www.enanta.com
52 Week Change -0.0546 Average Volume 174062 Forward Eps -4.82
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 464.90 %
Is_sp_500 False Regular Market Day High 9.28 Profit Margins -160.27 %
Debt To Equity 151.88 Fifty Two Week High 17.80 Day High 9.28
Shares Short 3 M Regular Market Open 8.51 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 2.60 Revenue Growth -4.90 %
Shares Percent Shares Out 0.1624 Operating Cashflow -89966000 Currency USD
Time Zone Full Name America/New_York Market Cap 187 M Is_nasdaq_100 False
Zip 02472 Quote Type EQUITY Industry Biotechnology
Long Name Enanta Pharmaceuticals, Inc. Overall Risk 6 Regular Market Day Low 8.49
Held Percent Institutions 1.01 Current Price 8.83 Enterprise To Ebitda -1.55
Financial Currency USD Current Ratio 4.92 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 8 Country United States
Float Shares 15 M Two Hundred Day Average 12.98 Governance Epoch Date 1 B
Enterprise Value 186 M Price To Sales Trailing12 Months 2.60 Forward PE -1.50
Regular Market Volume 233424 Ebitda -120341000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.

Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.

Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.